Envío gratis siempre a todo México.
Haz clic para hacer zoom
Not Available
Nektarios Oraiopoulos
From Breakthrough to Blockbuster
Cargando comentarios…
Comparte
$522
$496
(IVA Incluido)
Envío gratis siempre
Comentarios
Cargando el resumen…
Cargando comentarios…
product
777609From Breakthrough to Blockbusterhttps://www.gandhi.com.mx/from-breakthrough-to-blockbuster/phttps://gandhi.vtexassets.com/arquivos/ids/326804/255a9527-29e4-4e0d-b8fd-53ee8622407f.jpg?v=638334259469570000496522MXNOxford University PressInStock/Ebooks/<p><strong>Financial Times Business Top Title March 2022</strong> <strong>How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the worlds most breathtakingly expensive and highly regulated industries?</strong> Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40 more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. <em>From Breakthrough to Blockbuster: The Business of Biotechnology</em> focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.</p>...774620From Breakthrough to Blockbuster496522https://www.gandhi.com.mx/from-breakthrough-to-blockbuster/phttps://gandhi.vtexassets.com/arquivos/ids/326804/255a9527-29e4-4e0d-b8fd-53ee8622407f.jpg?v=638334259469570000InStockMXN99999DIEbook20229780197626306_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_<p><strong>Financial Times Business Top Title March 2022</strong> <strong>How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the worlds most breathtakingly expensive and highly regulated industries?</strong> Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40 more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. <em>From Breakthrough to Blockbuster: The Business of Biotechnology</em> focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.</p>(*_*)9780197626306_<p><strong>Financial Times Business Top Title March 2022</strong> <strong>How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the worlds most breathtakingly expensive and highly regulated industries?</strong> Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40 more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. <em>From Breakthrough to Blockbuster: The Business of Biotechnology</em> focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.</p>...9780197626306_Oxford University Presslibro_electonico_b3767b8a-4ae0-3f09-89b5-0619068d63d4_9780197626306;9780197626306_9780197626306Nektarios OraiopoulosInglésMéxicohttps://getbook.kobo.com/koboid-prod-public/oxfordupuk-epub-e4a518a1-8758-4a00-84a7-b0ead53562d2.epub2022-04-08T00:00:00+00:00Oxford University Press